In a comprehensive cohort study of two competing treatments (say, A and B), clinically eligible individuals are first asked to enroll in a randomized trial and, if they refuse, are then asked to enroll in a parallel observational study in which they can choose treatment according to their own preference. We consider estimation of two estimands: (1) comprehensive cohort causal effect -the difference in mean potential outcomes had all patients in the comprehensive cohort received treatment A vs. treatment B and (2) randomized trial causal effect -the difference in mean potential outcomes had all patients enrolled in the randomized trial received treatment A vs. treatment B. For each estimand, we consider inference under various sets of unconfoundedness assumptions and construct semiparametric efficient and robust estimators. These estimators depend on nuisance functions, which we estimate, for illustrative purposes, using generalized additive models. Using the theory of sample splitting, we establish the asymptotic properties of our proposed estimators. We also illustrate our methodology using data from the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial and observational registry to evaluate the effect of percutaneous transluminal coronary balloon angioplasty versus coronary artery bypass grafting on 5-year mortality. To evaluate the finite sample performance of our estimators, we use the BARI dataset as the basis of a realistic simulation study.
Introduction
Randomized controlled trials (RCTs) are considered to be the gold standard for comparing treatments, primarily because the experimental design probabilistically ensures that treatment groups are balanced with respect to measured and unmeasured prognostic factors. A well conducted RCT is said to have high internal validity. However, its external validity (i.e., generalizability of results to a broader population) is not guaranteed. This is because eligible patients who agree to enroll in an RCT may be not be a representative sample of all eligible patients. Due to the tension between internal and external validity, researchers have recommended that all clinically eligible patients, agreeing to randomization or not, should be enrolled and studied [Fielding et al., 1999] . Olschewski and Scheurlen [1985] introduced the comprehensive cohort study (CCS) design for evaluating competing treatments (say, A and B) in which clinically eligible participants are first asked to enroll in a randomized trial and, if they refuse, are then asked to enroll in a parallel observational study (OBS) in which they can choose treatment according to their own preference.
Most of the literature that describes methods for analyzing data from a CCS has focused on estimating treatment effects separately for the RCT and OBS (e.g., Olschewski et al. [1992] , Henshaw et al. [1993] , Nicolaides et al. [1994] , Schmoor et al. [1996] , King et al. [1997] , Detre et al. [1999] , Bedi et al. [2000] , , Kerry et al. [2000] , King et al. [2000] , Rovers et al. [2001] , Jensen et al. [2003] , Schmoor et al. [2008] ), with some adjustment for confounding in the OBS. With the exception of Olschewski et al. [1992] , King et al. [1997] and , there is no borrowing of information between the RCT and OBS.
Here, we focus on drawing causal inferences about treatment effects from a CCS, where the primary outcome (continuous or binary) is to be measured at a fixed point in time after treatment assignment. We are interested in drawing inference about two causal estimands: comprehensive cohort causal effectthe difference in mean potential outcomes had all patients in the CCS received treatment A vs. treatment B, and randomized trial causal effect -the difference in mean potential outcomes had all patients enrolled in the RCT received treatment A vs. treatment B. The comprehensive cohort causal effect is of interest because it refers to a broader population of eligible patients than those willing to participate in the randomized trial. The randomized trial causal effect is of interest because it is defined experimentally and its estimates would more confidently generalize to future patients with covariate profiles similar to those in the RCT.
The paper is organized as follows. In Section 2, we introduce notation, data structure, and main assumptions. Sections 3.2 and 3.3 present estimators and their properties for the comprehensive cohort causal effect and randomized trial causal effect, respectively. In Section 4, we illustrate our methods using data from the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial and observational registry to evaluate the effect of percutaneous transluminal coronary balloon angioplasty (PTCA) versus coronary artery bypass grafting (CABG) on 5-year mortality. Section D presents a simulation study, motivated by the BARI study, that evaluates the performance of our estimators. The last section is devoted to a discussion.
Notation and framework
Let X denote a vector of baseline covariates and let Y be the observed outcome (continuous or binary). Let R denote the randomization consent indicator (1 for RCT, 0 for OBS) and let T denote the treatment assignment indicator (1 for treatment A, 0 for treatment B). The observed data for an individual are O = (X ′ , Y, R, T) ′ . We assume n independent and identically distributed copies of O are drawn from some distribution P * contained in M. Throughout, the superscript * will be used to denote the true value of the quantity to which it is appended. The subscript i will denote data associated with individual i.
Let Y 1,r and Y 0,r be an eligible patient's potential outcome under treatment A and B, respectively, when enrolled into study r (r = 1 for RCT and r = 0 for OBS). We assume there is a single version of treatment (i.e., Y t,1 = Y t,0 = Y t for t = 0, 1; VanderWeele [2009] ).
Letting ν * t = E[Y t |R = 1], the randomized trial causal effect is defined as ∆ RCT = ν * 1 − ν * 0 . Letting µ * t = E[Y t ], the comprehensive causal effect is defined as ∆ CC = µ * 1 − µ * 0 . Our goal is to draw inference 
about ∆ RCT and ∆ CC . To identify these causal effects from the observed data, we posit assumptions sufficient for identification of ν * t and µ * t (t = 0, 1). We make the no interference assumption so that the potential outcomes of an individual are unaffected by the randomization consent and treatment decision of any other individual [Cox, 1958] . We make the consistency assumption that connects the observed outcomes to the potential outcomes via the following relation: VanderWeele, 2009] . In addition, we will utilize assumptions from among the following:
(A1) In the RCT, treatment is randomized: T⊥ (Y 1 , Y 0 , X) R = 1 (A2) In the OBS, treatment is randomized within levels of X:
We further impose positivity conditions so 0 < λ * 1 (x) < 1 and 0 < π * 1 (r, x) < 1 for all x and r = 0, 1 [Hernán and Robins, 2006] . We assume the first and second moments of the conditional distribution of Y t given R = r and X = x are finite for all x and r, t = 0, 1.
Note that under (A1) and (A2), Table 1 provides a complete list of our notation.
We consider inference about the comprehensive cohort causal effect under (A1) and (A2), under (A1) and (A3), and under (A1), (A2) and (A3), and inference about the randomized trial causal effect under (A1) and under (A1), (A2) and (A3). The two parameters will be equal if the causal effect in the OBS is equal to the causal effect in the RCT. This will occur when (A3) holds and either (i) the distribution of covariates is the same in the OBS and the RCT or (ii) there is no treatment effect heterogeneity.
In this paper, we derive, using semiparametric theory [Tsiatis, 2006 , Van der Laan and Robins, 2003 , Bickel et al., 1993 , efficient and robust estimators of these causal effects under these sets of assumptions. Marcus [1997] discussed assumptions similar to (A1) to (A3) for identifying the comprehensive cohort causal effect. The author discussed how unbiased estimates of the comprehensive cohort causal effect can be obtained using outcome/treatment/covariate data from RCT only, OBS only as well as the entire CCS. Our proposed estimator of the comprehensive causal effect under (A1) and (A2) and under (A1), (A2) and (A3) uses outcome/treatment/covariate data from the entire CCS and, under (A1) and (A3), uses outcome/treatment/covariate data from just the RCT.
Estimation of the randomized trial causal effect under (A1), (A2) and (A3) uses outcome/treatment/covariate data from the entire CCS. Conceptually, one can think of our approach as using data from the OBS to emulate the RCT [Hernán et al., 2008] and combining the resulting estimate with the estimate that uses RCT data only. If (A2) and (A3) are correct, we will have a more precise estimate of the randomized trial causal effect, but if the assumptions are wrong then the estimate may be biased. This bias-variance tradeoff may be appropriate in the setting of under-powered randomized trials. Figure 1 presents directed acyclic graphs (DAGs) that represents various combinations of assumptions. The dashed arrows in the figures indicate absence when R = 1 and presence when R = 0. Importantly, DAG (c), which encodes (A1), (A2) and (A3), induces testable restrictions, above and beyond (A1), on the distribution of the observed data; it implies that Y is independent of R given T and X. This holds because all paths from R to Y are blocked by T and X, which are non-colliders. Assuming (A1) holds, (A2) and (A3) can be tested by checking whether there is difference between the distribution of the observed outcome between those enrolled in the RCT and those enrolled in the OBS, after adjusting for treatment and covariates. If there is evidence of a difference, we cannot, unfortunately, tease out which of the two assumptions is misspecified. Note that the conditional independence statement does not hold in DAG (a) because of the unblocked paths R ← U → Y t → Y, t = 0, 1, and in DAG (b) because of the paths R → T ← U → Y t → Y, t = 0, 1, with the conditioning variable T being a collider.
Inference

Semiparametric Theory and Inferential Strategy
Under assumptions, the target parameters µ * t and ν t * can be written as functionals of the distribution of the observed data P * . Abstractly, define the functional by ψ(·) : M → R, with true value ψ * = ψ(P * ).
For sufficiently smooth functionals like those considered in this paper, it can be shown that
where (1) G is an analytic object depending on P and observation value o with E P [G(P)(O)] = G(P)(o)dP(o) = 0 and Var P [G(P)(O)] = G(P)(o) 2 dP(o) < ∞ and (2) Rem(P, P * ) is a "secondorder" remainder term that involves products of differences between P and P * (or their components) and tends to zero as P tends to P * . The object G can be viewed as a "gradient" as it measures, at any given data-generating distribution P, the change in ψ(P) following a slight perturbation of P. Equation (1) is called a von Mises expansion, a distributional version of a Taylor expansion [Bickel et al., 1993 , Carone et al., 2014 , Robins et al., 2017 .
Provided (1) holds and for a given estimator P of P * ,
where the first term on the right hand side represents the bias of the plug-in estimator. One way to estimate the bias is by − G( P)(o)dP n (o), where P n denotes the empirical distribution based on O 1 , O 2 , . . . , O n , to produce the corrected plug-in or one-step estimator
This estimator "uses the same data twice" and asymptotic theory will require the imposition of potentially restrictive Donkser conditions [Van der Vaart, 2000 ]. An alternative approach that works under weaker conditions is sample splitting [Chernozhukov et al., 2017 , Zheng and van der Laan, 2010 . The idea is to randomly split the observed data into K (approximately) equally-sized disjoint sets. Let S i be the split membership of the ith observation (i.e, S i ∈ {1, . . . , K}). LetP (−k) be the estimator of P * based on all the observed data except that of kth split, P (k) n k be the empirical distribution based on the n k (≈ n/K) observations in the kth split, and
The sample splitting estimator of ψ * is ψ = 1 K ∑ K k=1 ψ (k) . To understand the behavior of this estimator, we can write ψ − ψ * as 
converges in probability to zero (Regularity Condition 1), then √ n k R 1k will be o P * (1). Further, if P (−k) is a sufficiently well-behaved estimator of P * (i.e., converges at rates faster than n 1/4 ) and R 2k is second-order (Regularity Condition 2), then √ n k R 2k will be o P * (1). With n k = n/K,
where R k = R 1k + R 2k . Note that the second term on the right hand side will be o P * (1) since it is a finite sum of o P * (1) terms times a constant. The first term on the right hand side will converge in distribution, by the central limit theorem for i.i.d. data, to a normal random variable with mean zero and variance E[G(P * )(O) 2 ]. This shows that ψ is asymptotically linear with influence function G(P * )(O). The asymptotic variance of ψ can be estimated by 1 n ∑ K k=1 ∑ i:S i =k G( P (−k) )(O i ) 2 . Importantly, Equation (1) coupled with the asymptotically linearity of ψ will imply (under mild regularity conditions) that ψ is a "regular" [Newey, 1990] .
Although there may be many choices of G that satisfy (1), efficiency theory motivates the use of the canonical gradient, often called the efficient influence function, in the construction of the above estimator. The resulting estimator is then not only asymptotically linear but also asymptotically efficient relative to model M . The canonical gradient can be obtained by projecting any other gradient onto the tangent space, defined at each P ∈ M as the closure of the linear span of all score functions of regular one-dimensional parametric models through P. A comprehensive treatment of efficiency theory can be found in Pfanzagl [1982] and Bickel et al. [1993] .
The model M will be characterized by all distributions that satisfy the specified identification assumptions. Depending on the estimand and assumptions, the efficient influence curve will depend on P * through a subset of π * t1 (known),
The parameter λ * 1 is estimable at n 1/2 rates by λ 1 = ∑ i R i /n. In order to estimate the functions of X at fast enough rates, we will model them using generalized additive models (GAMs) in our simulations and application. We also use the rates of convergence for (GAMs) to illustrate our theoretical results. However, any desired method can be used as long as it provides the required rates of convergence. It is important to note that these models will induce a model for π * t (X), since π * t (X) = λ * 1 (X)π * t1 + (1 − λ * 1 (X))π * t (0, X). Under appropriate smoothness conditions (i.e., the functions of the continuous variables in the generalized additive models have two derivatives), the parameters of the models for λ * 1 (X), π * t (0, X), τ * t (X), τ * t (1, X), and τ * t (0, X) (and thus, π * t (X)) will be estimable at n 2/5 rates [Horowitz, 2009] . Where appropriate, we will comment on robustness of our estimators to model misspecification.
We will use semiparametric theory to compute the most efficient influence function in model M and use this to motivate the construction of asymptotically linear (AL) estimators µ * t and ν * t . Then ∆ * CC and ∆ * RCT can be estimated by the corresponding linear combinations of estimators for µ * 1 , µ * 0 , ν * 1 and ν * 0 ; linear combinations of AL estimators are AL. The key elements of the proofs of the theorems that appear in the next two subsections can be found in the Appendix.
Comprehensive Cohort Causal Effect
Theorem 1 Under (A1) and (A2), µ * t is identified via the following formulae:
The optimal influence function for µ * t is
The influence function G (A1,A2) µ t * (P * )(O) and resulting split-sampling estimator µ (A1,A2) t have the following properties:
•
• µ (A1,A2) t will be consistent provided the models for τ * t (0, X) or the model for π * t (0, X) is correctly specified; the model for τ * t (1, X) need not be correctly specified; • Under correct specification of models for τ * t (0, X) and π * t (0, X) and a possibly misspecified model for
will be regular and asymptotically linear with influence function G
where P * † is the true distribution of the observed data with τ * t (1, X) replaced with τ † (1, X) (asymptotic limit of τ (−k) t (1, X)).
The estimator µ (A1,A2) t uses treatment, outcome and covariate data from the entire CCS. The influence function is similar to the one discussed by Scharfstein et al. [1999] , Bang and Robins [2005] and Funk et al. [2011] .
Theorem 2 Under (A1) and (A3), µ t * is identified via the following formulae:
The influence function G
• Under correct specification of models for λ * 1 (X) and τ * t (1, X), µ (A1,A3) t will be regular and asymptotically
The estimator µ (A1,A3) t uses treatment/outcome/covariate data for all individuals in the RCT and covariate data for individuals in the OBS. The influence function is similar to the one discussed by Dahabreh et al. [2018] .
Theorem 3 Under (A1), (A2) and (A3), µ t * is identified via the following formulae:
The influence function G (A1,A2,A3) µ t * (P * )(O) and resulting split-sampling estimator µ (A1,A2,A3) t have the following properties:
is consistent provided the model for π * t (X) or the model for τ * t (X) is correctly specified;
• Under correct specification of models for π * t (X) and τ * t (X), µ (A1,A2,A3) t will be regular and asymptotically linear with influence function G
The estimator µ (A1,A2,A3) t , uses treatment, outcome and covariate data from the entire CCS. Under Assumptions (A1), (A2) and (A3) and correct model specification, µ (A1,A2,A3) t will be as or more efficient than µ
Randomized Trial Causal Effect
Theorem 4 Under (A1), ν * t is identified via the following formulae:
The influence function G (A1) ν t * (P * )(O) and resulting split-sampling estimator ν (A1) t have the following properties:
• Under a possibly misspecified model for
The estimator ν (A1) t uses treatment/outcome/covariate data for all individuals in the RCT. It will be consistent even if the model for τ * t (1, X) is incorrectly specified. The influence function is the same as that discussed in Chapter 13 of Tsiatis [2006] . Imposing either (A2) or (A3), above and beyond (A1), does not result in any efficiency improvement.
Theorem 5 Under (A1), (A2) and (A3), ν * t is identified via the following formulae:
The influence function G (A1,A2,A3) ν t * (P * )(O) and resulting split-sampling estimator ν (A1,A2,A3) t have the following properties:
will be consistent provided the model for τ * t (X) is correctly specified or the models for λ * 1 (X) and π * t (0, X) are correctly specified.
• Under correct specification of models for π * t (X) and τ * t (X), ν (A1,A2,A3) t will be regular and asymptotically linear with influence function G
The estimator ν (A1,A2,A3) t uses treatment/outcome/covariate data from the entire CCS.
Remarks:
Although the estimators µ (A1,A2) t , µ (A1,A3) t and ν (A1,A2,A3) t are doubly robust with respect to consistency, achieving doubly robust inference (i.e., constructing confidence intervals with nominal coverage even if one of the modeling conditions is misspecified) is not straightforward in nonparametric settings. We refer to and Benkeser et al. [2017] for recent progress on this problem. An alternative would be to use parametric models, for which the contribution to the variance is more straightforward to derive under misspecification. Although this would allow doubly robust inference, it would come at the cost of making much more restrictive assumptions on the nuisance functions. Since our approach only requires relatively slow second-order rate conditions (e.g., n 1/4+ǫ rates), the nuisance functions can be modeled flexibly, thereby reducing the risk of misspecification (making doubly robust inference a less crucial goal).
Analysis of BARI
BARI was designed to compare survival in patients receiving either PTCA or CABG. As summarized in , a comprehensive cohort design was adopted and included 3,839 patients who had severe angina or ischemia and multivessel coronary artery disease suitable for initial revascularization by either PTCA or CABG, and who were willing to be followed up. Among these patients, 1,829 patients consented to randomization and entered a randomized trial. The remaining 2,010 patients refused randomization but agreed to participate in the BARI registry, in which patients could choose their initial treatment in consultation with their physician. The follow-up plan was similar for randomized (RCT) and registry (OBS) patients.
In our re-analysis of the BARI study, we excluded 196 registry patients who did not receive treatment within 3 months of study entry as well as 33 RCT patients who did not receive their assigned treatment. Our analysis utilized information on 12 baseline variables: age, sex, highest level of education, systolic blood pressure, diastolic blood pressure, qualifying symptoms (unstable angina/MI vs. other), number of diseased vessels (three vs. less than three), proximal left anterior descending disease, prior myocardial infarction, diabetes (no, with treatment, without treatment), current smoking, hypertension. All variables are categorical except age, systolic blood pressure and diastolic blood pressure which are continuous. Patients missing at least one of these covariates (n = 149) were excluded. Finally, four patients with less than five years of follow-up and known to be alive at last follow-up were excluded. Thus, our analysis included data on 3,457 patients (1,695 from OBS and 1,762 from RCT). Among RCT patients, 888 (50.4%) received PTCA and among OBS patients, 1,108 (65.4%) chose and received PTCA. Table 2 presents the baseline characteristics of patients, stratified by study type and treatment. The table shows that, in aggregate, patients who enrolled in the RCT tended to be slightly sicker than those who enrolled in the OBS. Further stratifying by treatment group reveals more stark differences between RCT and OBS patients, especially with respect to number of diseased vessels and proximal left anterior descending disease. Since consenting to participate in an RCT is a personal patient decision, it is possible that there may be differences between RCT and OBS patients with respect to unmeasured factors such as self-efficacy and health behaviors (i.e., (A3) may be violated). Within the RCT, the two treatments were well balanced with respect to the baseline factors. Within the OBS, we see that CABG patients tend to have more severe disease than PTCA patients. Within the OBS, the selection of PTCA as compared to CABG is largely based on the patients' coronary anatomy and symptoms. Physicians play a critical role in advising patients regarding procedure selection, and physician decisions are generally based on objective clinical and angiographic criteria. It is therefore plausible that we have accounted for the most important prognostic factors that are related to treatment selection within the OBS (i.e., (A2) is reasonable). In the RCT, the proportion of patients who died by five years was 13.40% and 10.30% in the PTCA and CABG arms, respectively. In the OBS, the death rate was uniformly lower with 7.94% and 8.86% of PTCA and CABG patients dying, respectively.
In our analysis, R denotes the randomization consent indicator, T denotes the indicator of receiving PTCA, Y denotes the indicator of death by the end of 5 years and X is the vector of baseline variables. We evaluated (A2) and (A3) by fitting, separately by treatment group, a generalized additive logistic regression model for the probability of dying by the end of 5 years as a function of the randomization consent indicator, the categorical variables (treated as factors) as well as smooth functions of age, systolic blood pressure and diastolic blood pressure. In the PTCA model, the estimated conditional odds ratio of dying for patients enrolled in the RCT versus OBS was 1.68 (95% CI: 1.09 to 2.58) providing statistical evidence against (A2) and (A3). In the CABG model, the estimated conditional odds ratio of dying for patients enrolled in the RCT versus OBS was 1.13 (95%: 0.66 to 1.96), yielding equivocal evidence against (A2) and (A3). Despite evidence against (A2) and (A3), we proceeded, for illustrative purposes, to estimate µ * t and ν * t under various combinations of assumptions. Towards this end, we fit generalized additive logistic regression models for λ *
, and τ * 0 (0, X). Our sample splitting estimators were based on K = 5 splits. Table 3 displays the estimated comprehensive cohort and randomized trial causal effects (along with standard errors and 95% Wald-based confidence intervals) under the different assumptions.
For the comprehensive cohort causal effect, the estimator under (A1) and (A2) has greater precision than that under (A1) and (A3). Comparatively speaking, the latter estimator is further from the null with an associated 95% confidence interval that excludes the null. The estimator that imposes all three assumptions was closer to the estimator under (A1) and (A2) than under (A1) and (A3). For the randomized trial causal effect, the estimator under (A1), (A2) and (A3) has, as expected, greater precision than that under (A1). The former estimator is further from the null, with a 95% confidence interval that excludes the null. Given the evidence against (A2) and (A3) in the PTCA arm, the only trustworthy estimator is the randomized trial causal effect. Thus, our analysis cannot provide evidence that effect seen in the RCT generalizes to the entire cohort. Our findings are largely consistent with the findings of BARI Investigators [1996] and Feit et al. [2000] . 1.53% 0.06% to 6.05% (A1), (A2), (A3) ν * 1 11.00% 0.77% 9.49% to 12.51% ν * 0 9.92% 0.80% 8.36% to 11.49% ∆ * RCT 1.07%
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Simulation studies
In the Appendix D, we present simulation studies, motivated by the BARI study, to evaluate the performance of the five proposed estimators. We consider three simulation studies, corresponding to the three sets of assumption represented in Figure 1 . For each set of assumptions, we consider various model misspecification scenarios. Since we have assumed that (A1) holds for all scenarios and ν (A1) t is immune to model misspecification, all simulations demonstrate that it is unbiased, with excellence correspondence between the average standard error and standard deviation of parameter estimates and coverage of 95% confidence intervals close to their nominal level. The other estimators performed consistent with theory.
Conclusion and Discussion
In this paper, we presented methods for estimating causal effects of a binary treatment in the CCS design. We discussed three estimators of the comprehensive cohort causal effect and two estimators for the randomized trial causal effect. For the comprehensive cohort casual effect estimators, our data analysis and simulation study suggest that the estimator that uses (A1) and (A2) is more efficient than the estimator that utilizes (A1) and (A3). In fact, it is possible to manufacture data generating scenarios where the opposite is true. The choice between the estimators should ultimately rely on substantive tenability of the underlying assumptions.
For the randomized trial causal effect estimators, ν one is interested in the randomized trials causal effect, the estimator may be a viable way of obtaining more precise inferences. More detailed study of the bias-variance tradeoff associated with using data from OBS to estimate the RCT effect is warranted. Finally, for both estimands, the methods in this paper need to be extended to deal with noncompliance, missing data, time-varying treatments and censored outcomes.
Appendices
In what follows, we define π * t (0, X, Y 1 , Y 0 ) = P[T = t|R = 0, X, Y 1 , Y 0 ]. It is also useful to note that any observed data random variable can be written as:
A Orthogonal Complement of Tangent Spaces
A.1 Assumption (A1)
The observed data tangent space is:
We must now find elements of A ⊥ that are in B ⊥ . We first note that
A.2 Assumption (A1,A2)
We must now find elements of A ′ ⊥ that are in B ′ ⊥ . We first note that R(T − π * 11 )h(X) is in B ′ ⊥ for all h(X). We now seek additional conditions on b(X) such that (1 − R)(T − π * 1 (0, X))h(X) is in B ⊥ . Since (1 − R)(T − π * 1 (0, X))h(X) ∈ B for all h(X), it must be the case that h(X) = 0. Thus,
A.3 Assumption (A1,A3)
We must now find elements of A †⊥ ∩ B †⊥ that are in C †⊥ . The additional condition on h 1 (X), h 2 (X) and h(X) is
This implies that π * 11 h 1 (X) + π * 01 h 2 (X) − h(X) = 0. Further imposing the condition from A †⊥ ∩ B †⊥ , we have h(X) = 0 and h 2 (X) = − π * 11 π * 01 a 1 (X). Thus, T ⊥ = {R(T − π * 11 )a(X) : a(X)}.
A.4 Assumption (A1,A2,A3)
Let's find elements of A ‡⊥ that are in B ‡⊥ . The additional condition on h
After algebra, we can then write
B Efficient Influence Functions and Estimators
For a given set of assumptions, the efficient influence for a target parameter is a naive influence function minus its projection onto the orthogonal complement of the tangent space.
B.1 Assumption (A1)
Under (A1), µ * t is not identified and so there are no influence functions to discuss. However, ν * t is identified and a naive influence function is
The projection reduces to
be the plug-in estimator based on data excluding the kth split. The resulting estimator based on the kth split is
B.2 Assumption (A1,A2)
Under (A1,A2), µ * t is identified and a naive influence function is
So, the efficient influence function for µ * t is
The resulting estimator based on the kth split is
the efficient influence curve under (A1,A2) is the same as under (A1), since T ⊥ is the same.
B.3 Assumption (A1,A3)
Under (A1,A3), µ * t is identified and a naive influence function is
For ν * t , the efficient influence curve under (A1,A3) is the same as under (A1), since T ⊥ is the same.
B.4 Assumption (A1,A2,A3)
The projection of any observed data random variable h
So, the efficient influence function for ν * t is
be the plug-in estimator based on data excluding the kth split. The resulting estimator based on the kth split iš
C Asymptotics
C.1 Theorem 1
It can be shown that
Letting P be the estimator P (−k) and assuming π (−k) t (R, X) is bounded away from zero with probability 1, it follows that
where C (−k) is O P * (1). This implies that that Regularity Condition 2 holds and √ n k R 2k is o P * (1).
In terms of R 1k is useful to notice that it is equal to
Using the triangle and Cauchy-Schwarz inequalities, it can be shown that
where D
is o P * (1) (i.e., Regularity Condition 1 holds) and √ n k R 1k is o P * (1).
C.2 Theorem 2
Letting P be the estimator P (−k) and assuming λ (−k) 1 (X) is bounded away from zero with probability 1, it follows that
. This implies that that Regularity Condition 2 holds and √ n k R 2k is o P * (1)
In terms of R 1k , we note that it is equal to
is o P * (1) (i.e., Regularity Condition 1 holds) and
√ n k R 1k is o P * (1)
C.3 Theorem 3
Letting P be the estimator P (−k) and assuming π (−k) t (X) is bounded away from zero with probability 1, it follows that
is o P * (1) (i.e., Regularity Condition 1 holds) and √ n k R 1k is o P * (1)
C.4 Theorem 4
Letting P be the estimator P (−k) , it follows that
are O P * (1). Thus, Regularity Condition 1 holds and √ n k R 1k is o P * (1)
C.5 Theorem 5
are O P * (1). This implies that that Regularity Condition 2 holds and √ n k R 2k is o P * (1)
and D (−k) 5 that are O P * (1). Thus, Regularity Condition 1 holds and √ n k R 1k is o P * (1)
D Simulation studies
We present simulation studies, motivated by the BARI study, to evaluate the performance of the five proposed estimators. We consider three simulation studies, corresponding to the three sets of assumption represented in Figure 1 of the manuscript. For each set of assumptions, we consider various model misspecification scenarios. We simulated 5000 datasets, each with a sample size of n = 2000. Datasets were analyzed with K = 5 sample splits. We report average bias, average of standard error estimate, Monte Carlo standard deviation of the estimator, coverage of 95% Wald confidence intervals and Monte Carlo mean squared error for the three estimators of µ * 1 and µ * 0 and for the two estimators of ν * 1 and ν * 0 . Since we have assumed that (A1) holds for all scenarios and ν (A1) t is immune to model misspecification, all simulations demonstrate that it is unbiased, with excellence correspondence between the average standard error and standard deviation of parameter estimates and coverage of 95% confidence intervals close to their nominal level.
D.1 Study 1: Assumptions (A1) and (A2)
In this simulation study, we let λ * 1 (X), π * 1 (0, X) , τ * 1 (0, X) and τ * 0 (0, X), be equal to the estimated functions obtained from fitting the generalized additive logistic models to the BARI data. We generated data according to the following procedure:
1. Draw X from the empirical distribution of the 12 covariates utilized in our analysis of the BARI study;
2. Draw U ∼ Normal(0, 1) independent of X; ·, a, b) is the cumulative distribution function of a normal random variable with mean a and variance b; ·; a, B) is the cumulative distribution function of a bivariate normal random vector mean a and variance-covariance matrix B and Σ is a variance-covariance matrix with variance 1 and covariance 2. For t = 0, 1, draw Y t ∼ Bernoulli(Φ(∆ Y t (X) + U; 0, 1))
Steps 3 and 5 use the idea of generating correlated binary outcomes discussed by Swihart et al. [2014] ; the conditional distribution of R given X is Bernoulli(λ * 1 (X)) and the conditional distribution of Y t given R = 0 and X is Bernoulli(τ * t (0, X)). Table 4 presents the results of the simulation study. In addition to evaluating the five estimators under correct model specification -(a), we considered the following three misspecification scenarios:
(b) π 1 (0, X) is replaced by Φ(logit{ π 1 (0, X)}; 0, 25);
(c) τ t (0, X) is replaced by Φ(logit{ τ t (0, X)}; 0, 25);
(d) π 1 (0, X) and τ t (0, X) are replaced by Φ(logit{ π 1 (0, X)}; 0, 25) and Φ(logit{ τ t (0, X)}; 0, 25), respectively. Table 4 shows that, when either the model for π * t (0, X) or τ * t (X) is modeled correctly, then µ Table 6 : Simulation results: (A1), (A2), (A3) (continued) (e) λ * 1 (X), π * t (0, X) modeled incorrectly, τ * t (X) = τ * t (1, X) = τ * t (0, 
E R Code
We refer to the data frame for the dataset as datc, let n denote the sample size and let K denote the number of sample splits. We store the sample split results for each of the five estimators in matrices named resmua1a2, resmua1a3, resmua1a2a3, resnua1 and resnua1a2a3, respectively. Here is sample R code.
In the R code, the covariates have the following naming conventions: age (AGE), sex (SEX), highest level of education (EDUC), systolic blood pressure (SBP), diastolic blood pressure (DBP), qualifying symptoms (unstable angina/MI vs. other; ANGTYPE), number of diseased vessels (three vs. less than three; DISREGB), proximal left anterior descending disease (TSPLADD), prior myocardial infarction (MI), diabetes (no, with treatment, without treatment; DIAB), current smoking (CIG), hypertension (HYPER). In addition, R denotes the randomization consent indicator, PTCA denotes the indicator of receiving PTCA and DEATH denotes the binary indicator of death by the end of 5 years (DEATH).
K=5 # number of sample splits resmua1a2 = matrix(0,K,4) resmua1a3 = matrix(0,K,4) resmua1a2a3 = matrix(0,K,4) resnua1 = matrix(0,K,6) resnua1a2a3 = matrix (0, , family=binomial, data = datmk, subset = (R==0)) pgamtres0mk = predict.Gam(gamtres0mk,datmk,type='response') pgamtres0k = predict.Gam(gamtres0mk,datk,type='response') # estimated conditional probability of death under PTCA (CABG) given study and covariates # estimated on minus kth split and kth split tau1rxmk = pgamyres11mk * (datmk$R==1) + pgamyres01mk * (datmk$R==0) tau0rxmk = pgamyres10mk * (datmk$R==1) + pgamyres00mk * (datmk$R==0) tau1rxk = pgamyres11k * (datk$R==1) + pgamyres01k * (datk$R==0) tau0rxk = pgamyres10k * (datk$R==1) + pgamyres00k * (datk$R==0) # estimated conditional probability of death under PTCA (CABG) given covariates # estimated on minus kth split and kth split tau1xmk = pgamyres1mk tau0xmk = pgamyres0mk tau1xk = pgamyres1k tau0xk = pgamyres0k # probability of PTCA in RCT for minus kth split and kth split pi11mk = 0.5 pi11k = 0.5 # marginal probability of study type for minus kth split and kth split lambda1mk = mean(datmk$R) lambda1k = mean(datk$R) # estimated conditional probability of PTCA (CABG) given study and covariates # estimated on minus kth split and kth split pi1rxmk = pgamtres0mk * (datmk$R==0) + pi11mk * (datmk$R==1) pi0rxmk = (1-pgamtres0mk) * (datmk$R==0) + (1-pi11mk) * (datmk$R==1) pi1rxk = pgamtres0k * (datk$R==0) + pi11mk * (datk$R==1) pi0rxk = (1-pgamtres0k) * (datk$R==0) + (1-pi11mk) * (datk$R==1) # estimated conditional probability of PTCA (CABG) given covariates # estimated on minus kth split and kth split pi1xmk = pgamrresmk * pi11mk + (1-pgamrresmk) * pgamtres0mk pi0xmk = pgamrresmk * (1-pi11mk) + (1-pgamrresmk) * (1-pgamtres0mk) pi1xk = pgamrresk * pi11mk + (1-pgamrresk) * pgamtres0k pi0xk = pgamrresk * (1-pi11mk) + (1-pgamrresk) * (1-pgamtres0k) [k,4] = resnua1a2a3[k,2] + mean((datk$PTCA==0)*pgamrresk*(datk$DEATH)/(lambda1mk*(1-pi1xk)) + (datk$R-(datk$PTCA==0)*pgamrresk/(1-pi1xk))*tau0xk/lambda1mkdatk$R/lambda1mk*resnua1a2a3[k,2]) resnua1a2a3[k,5] = sum(((datk$PTCA==1)*pgamrresk*(datk$DEATH)/(lambda1mk*pi1xk) + (datk$R-(datk$PTCA==1)*pgamrresk/pi1xk)*tau1xk/lambda1mkdatk$R/lambda1mk*resnua1a2a3[k,3])^2) resnua1a2a3[k,6] = sum(((datk$PTCA==0)*pgamrresk*(datk$DEATH)/(lambda1mk*(1-pi1xk)) + (datk$R-(datk$PTCA==0)*pgamrresk/(1-pi1xk))*tau0xk/lambda1mkdatk$R/lambda1mk*resnua1a2a3[k,4])^2) } # Estimates, standard errors and confidence intervals of mu, nu mua1a2 = apply(resmua1a2,2,mean)[1:2] semua1a2 = sqrt(apply(resmua1a2,2,sum)/n^2)[3:4] lcimua1a2 = mua1a2 -1.96*semua1a2 ucimua1a2 = mua1a2 + 1.96*semua1a2 mua1a3 = apply(resmua1a3,2,mean)[1:2] semua1a3 = sqrt(apply(resmua1a3,2,sum)/n^2)[3:4] lcimua1a3 = mua1a3 -1.96*semua1a3 ucimua1a3 = mua1a3 + 1.96*semua1a3 mua1a2a3 = apply(resmua1a2a3,2,mean)[1:2] semua1a2a3 = sqrt(apply(resmua1a2a3,2,sum)/n^2)[3:4] lcimua1a2a3 = mua1a2a3 -1.96*semua1a2a3 ucimua1a2a3 = mua1a2a3+ 1.96*semua1a2a3 nua1 = apply(resnua1,2,mean)[3:4] senua1 = sqrt(apply(resnua1,2,sum)/n^2)[5:6] lcinua1 = nua1 -1.96*senua1 ucinua1 = nua1 + 1.96*senua1 nua1a2a3 = apply(resnua1a2a3,2,mean)[3:4] senua1a2a3 = sqrt(apply(resnua1a2a3,2,sum)/n^2)[5:6] lcinua1a2a3 = nua1a2a3 -1.96*senua1a2a3 ucinua1a2a3 = nua1a2a3 + 1.96*senua1a2a3 # Estimates, standard errors and confidence intervals of treatment effects deltamua1a2 = mua1a2[1]-mua1a2[2] sedeltamua1a2 = sqrt(sum(semua1a2^2)) cideltamua1a2 =c(deltamua1a2-1.96*sedeltamua1a2, deltamua1a2+1.96*sedeltamua1a2) deltamua1a3 = mua1a3[1]-mua1a3[2] sedeltamua1a3 = sqrt(sum(semua1a3^2)) cideltamua1a3 =c(deltamua1a3-1.96*sedeltamua1a3, deltamua1a3+1.96*sedeltamua1a3) deltamua1a2a3 = mua1a2a3[1]-mua1a2a3[2] sedeltamua1a2a3 = sqrt(sum(semua1a2a3^2)) cideltamua1a2a3 =c(deltamua1a2a3-1.96*sedeltamua1a2a3, deltamua1a2a3+1.96*sedeltamua1a2a3) deltanua1 = nua1[1]-nua1[2] sedeltanua1 = sqrt(sum(senua1^2)) cideltanua1 =c(deltanua1-1.96*sedeltanua1, deltanua1+1.96*sedeltanua1) deltanua1a2a3 = nua1a2a3[1]-nua1a2a3[2] sedeltanua1a2a3 = sqrt(sum(senua1a2a3^2)) cideltanua1a2a3 =c(deltanua1a2a3-1.96*sedeltanua1a2a3, deltanua1a2a3+1.96*sedeltanua1a2a3)
